Evaluation of Lactate Dehydrogenase and Alkaline Phosphatase as Predictive Biomarkers in the Prognosis of Hepatocellular Carcinoma and Development of a New Nomogram
Ke Su,Weihong Huang,Xueting Li,Ke Xu,Tao Gu,Yanlin Liu,Juan Song,Keyi Qian,Yaoyang Xu,Hao Zeng,Yipei Yang,Lu Guo,Yunwei Han
DOI: https://doi.org/10.2147/JHC.S398632
2023-01-15
Journal of Hepatocellular Carcinoma
Abstract:Ke Su, 1, &ast Weihong Huang, 2, &ast Xueting Li, 3, &ast Ke Xu, 4, &ast Tao Gu, 1 Yanlin Liu, 1 Juan Song, 2 Keyi Qian, 5 Yaoyang Xu, 2 Hao Zeng, 1 Yipei Yang, 6 Lu Guo, 7 Yunwei Han 1 1 Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, People's Republic of China; 2 Clinical Medical College, Southwest Medical University, Luzhou, 646000, People's Republic of China; 3 Department of Oncology, 363 Hospital, Chengdu, 610041, People's Republic of China; 4 Department of Oncology, Chongqing General Hospital, Chongqing, 401147, People's Republic of China; 5 Department of Nursing, Sichuan University, Chengdu, 610065, People's Republic of China; 6 Department of Orthopedic Surgery, Shenzhen Hospital, Southern Medical University, Shenzhen, 518000, People's Republic of China; 7 Department of Ophthalmology, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yunwei Han; Lu Guo, The Affiliated Hospital of Southwest Medical University, 25 TAIPING Street, Luzhou City, Sichuan Province, People's Republic of China, Tel +86-830-3165598 ; +86-830-3165613, Email ; Background: Tumor proliferation is frequently accompanied by aberrant enzyme production. We aim to investigate the potential predictive value of both plasma alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) in patients with HCC and to develop a nomogram to assess the prognosis of HCC. Methods: The trial involved 2327 patients between May 2015 and March 2022. Within 7 days of enrollment, the levels of ALP and LDH were measured, and their association with survival was assessed. And we had developed and validated a new nomogram based on ALD and ALP. Results: Using X-tile software, the optimal cut-off values were determined to be ALP = 172 U/L and LDH = 241 U/L. The high ALP (≥ 172), LDH (≥ 241), and ALP/LDH (≥ 0.91) groups had lower median overall survival (mOS) than low ALP (< 172), LDH (< 241), and ALP/LDH (< 0.91) groups (all p < 0.001). In addition, elevated ALP and LDH levels are independent negative prognostic indicators. Moreover, we established that the area under the curve (AUC) values of the predicted 1-, 2-, and 3-year survival rates of receiver operating characteristic curve (ROC) based on the nomogram were 0.79, 0.77, and 0.74, respectively. In addition, the calibration curves and decision curve analyses (DCA) demonstrated that this model possessed strong predictive capability. Conclusion: ALP, LDH and ALP/LDH can be employed as biomarkers for predicting the prognosis of HCC. Furthermore, the nomograph based on ALH and ALP demonstrates good HCC prediction performance. For HCC patients with high ALH or ALP or ALP/LDH, close surveillance program and adjuvant therapy should be considered. Keywords: lactate dehydrogenase, alkaline phosphatase, hepatocellular carcinoma, overall survival, nomogram Hepatocellular carcinoma (HCC) is a prevalent malignant tumor that is anticipated to impact over 1 million people annually by 2025. 1,2 The majority of HCC patients are in an advanced state at the time of diagnosis. Advanced HCC currently faces the challenge of a median overall survival (mOS) of 5.5 months. 3 Therapeutic options for advanced HCC are limited. Surgery still remains frequently curative therapy for HCC, however, the long-term prognosis after resection remains unsatisfactory, due to the high disease relapse rate. Recently approved systemic agents do offer more options for the treatment of advanced HCC patients. Still, the lack of head-to-head comparative studies between first- and second-line treatments leads to confusion when making clinical decisions. Currently, the US Food and Drug Administration has approved atezolizumab plus bevacizumab as the treatment of choice for unresectable HCC. 4 In addition, a large Phase II/III study revealed that sintilimab + bevacizumab biosimilar was superior to sorafenib monotherapy in patients with unresectable HCC. 5 With a 5-year OS of 52.0 and a 5-year disease free survival (DFS) of 41.4, radiofrequency ablation (RFA) + transarterial chemoembolization (TACE) for the same aim shown good efficacy in early-stage HCC. 6 Although the problem of HCC patients' low life expectancy has been alleviated, the challenge of gauging the treatment's effectiveness remains. Alpha-fetoprotein (AFP), a tumor-associated protein found in serum, is frequent -Abstract Truncated-
oncology